Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04817566
Other study ID # NeuroMod-PCCI
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 2, 2021
Est. completion date August 2024

Study information

Verified date June 2023
Source University Medicine Greifswald
Contact Agnes Flöel, Prof.
Phone 0049 3834 86 6815
Email agnes.floeel@med.uni-greifswald.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate whether a high definition tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in women with post-chemotherapy cognitive impairment after breast cancer treatment.


Description:

Patients who have undergone chemotherapy, may develop post-chemotherapy cognitive impairment (PCCI), which may occur in several cognitive domains and persist for many years. These declines in cognitive functions can lead to psychological distress and affect overall patients' quality of life. The goal of the present study is to assess behavioral effects of a multi-session cognitive training combined with high-definition transcranial direct current stimulation (tDCS) in women with PCCI. First studies have shown positive effects of cognitive training on trained and untrained functions and the subjective perception of stress, however the effects are small and transfer effects are inconsistent. A promising approach to elongate and increase the effects of cognitive training is to combine the training with tDCS. Therefore, in this study women with PCCI will participate in a three-week cognitive training with concurrent online high-definition tDCS application. Cognitive performance (primary), as well as Quality of Life scores and Sleep data will be examined before, during and after the intervention. In order to draw conclusions about the effect of tDCS in addition to cognitive training, a control group, receiving sham stimulation during training, will be assessed. A Follow-up session to assess long-term effects is planned four weeks after the post assessment. The results of the study will offer valuable insights into efficacy of combined tDCS and cognitive training intervention in women with PCCI in order to establish its potential to induce improvements in cognitive functions, and to beneficially affect patient-reported outcome measures.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date August 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Chemotherapy to treat breast cancer (= 6 months post-treatment). 2. Self-reported concerns regarding cognitive functioning. 3. Age: 18-60 years. Exclusion Criteria: 1. History of dementia before treatment of cancer. 2. Other neurodegenerative neurological disorders; epilepsy or history of seizures. 3. Severe and untreated medical conditions that preclude participation in the training, as determined by responsible physician. 4. History of moderate to severe substance use disorder according to DSM-5 5. Moderate to severe acute psychiatric disorders according to DSM-5 6. Contraindication to tDCS application (Antal et al., 2017)

Study Design


Intervention

Device:
Anodal tDCS
Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
Sham tDCS
Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
Behavioral:
Intensive cognitive training
Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min

Locations

Country Name City State
Germany University Medicine Greifswald Greifswald

Sponsors (2)

Lead Sponsor Collaborator
University Medicine Greifswald University of Greifswald

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Working memory performance at post-assessment Performance in a near transfer task (n-back) under anodal tDCS compared to sham condition; operationalized by % correct responses in the n-back task 3 weeks
Secondary Working memory performance at follow-up assessment Performance in a near transfer task (n-back) under anodal tDCS compared to sham condition; operationalized by % correct responses in the n-back task 4 weeks after training
Secondary Working memory training performance (Letter Updating Task) at post-assessment Performance in primary memory training task (Letter Updating Task) at post-assessment, operationalized by number of correctly recalled lists in the letter updating task 3 weeks
Secondary Working memory training performance (Letter Updating Task) at follow-up assessment Performance in primary memory training task (Letter Updating Task) at follow-up assessment, operationalized by number of correctly recalled lists in the letter updating task 4 weeks after training
Secondary Quality of Life at post-assessment PROMIS score for HRQoL (PROPr score) and scores of subscales (e.g. cognitive function) 3 weeks
Secondary Quality of Life at follow-up assessment PROMIS score for HRQoL (PROPr score) and scores of subscales (e.g. cognitive function) 4 weeks after training
Secondary Visuo-spatial performance at post-assessment Visuo-spatial performance at post-assessment operationalized by number of correctly recalled items in the VR task. 3 weeks
Secondary Visuo-spatial performance at follow-up assessment Visuo-spatial performance at follow-up assessment operationalized by number of correctly recalled items in the VR task. 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A